SABATO has been going on for quite a while now!
Question: is switching to oral therapy for low risk SAB possible?
Low risk: negative follow-up BC, no mestatistic infection, intravascular catheters removed, no prosthetic vascular material, not immunosuppressed
Question: is switching to oral therapy for low risk SAB possible?
Low risk: negative follow-up BC, no mestatistic infection, intravascular catheters removed, no prosthetic vascular material, not immunosuppressed
Benefits and risks: 
Design:
Study meds:
Reasonable choices, but noting that trimethoprim-sulfa inferior to vanc in Paul et al study for MRSA.
Reasonable choices, but noting that trimethoprim-sulfa inferior to vanc in Paul et al study for MRSA.
CONSORT diagram:
Ended up with smallish numbers still - 108 in oral and 105 in IV arms.
Baseline characteristics:
Only 5% MRSA. Line related infections about 60%.
Baseline characteristics:
Only 5% MRSA. Line related infections about 60%.
Results:
No difference between treatment arms.
Certainly no difference in per protocol populations which the presentation focussed on.
Wasn't clear in presentation what the pre-defined non-inferiority margin was. If 5% then in the ITT may not have been NI.
No difference between treatment arms.
Certainly no difference in per protocol populations which the presentation focussed on.
Wasn't clear in presentation what the pre-defined non-inferiority margin was. If 5% then in the ITT may not have been NI.
Have looked at the trial protocol. The NI margin was intially 5% but then in the updated protocol increased to 10%. So looks like it meets the NI margin of 10% in the ITT for the primary outcome of SAB related complication in 90d: 0.007 (-0.078 to 0.091).
• • •
Missing some Tweet in this thread? You can try to
force a refresh
